Lenz Therapeutics Stock Today
| LENZ Stock | 35.50 1.18 3.44% |
Performance14 of 100
| Odds Of DistressLess than 41
|
LENZ Therapeutics is trading at 35.50 as of the 25th of November 2024; that is 3.44 percent increase since the beginning of the trading day. The stock's open price was 34.32. LENZ Therapeutics has about a 41 percent probability of financial distress in the next few years of operation but had a somewhat good performance during the last 90 days. LENZ Therapeutics symbol was changed from GRPH on 22nd of March 2024. Equity ratings for LENZ Therapeutics are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 1st of December 2023 and ending today, the 25th of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 25th of June 2021 | Category Healthcare | Classification Health Care |
LENZ Therapeutics is entity of United States. It is traded as Stock on NASDAQ exchange. The company has 27.47 M outstanding shares of which 2.07 M shares are now shorted by private and institutional investors with about 17.72 trading days to cover. More on LENZ Therapeutics
Moving against LENZ Stock
LENZ Stock Highlights
| Older Symbol | GRPH | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| CEO and Presidentident | Evert Schimmelpennink | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Old Name | Sancus Lending Group Ltd. ZDP | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
LENZ Therapeutics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand LENZ Therapeutics' financial leverage. It provides some insight into what part of LENZ Therapeutics' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
LENZ Therapeutics (LENZ) is traded on NASDAQ Exchange in USA. It is located in 445 Marine View Avenue, Del Mar, CA, United States, 92014 and employs 10 people. LENZ Therapeutics was previously known as Graphite Bio and was traded on NASDAQ Exchange under the symbol GRPH. LENZ Therapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 600.49 M. LENZ Therapeutics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 27.47 M outstanding shares of which 2.07 M shares are now shorted by private and institutional investors with about 17.72 trading days to cover.
LENZ Therapeutics generates negative cash flow from operations
Check LENZ Therapeutics Probability Of Bankruptcy
Ownership AllocationLENZ Therapeutics maintains a total of 27.47 Million outstanding shares. The majority of LENZ Therapeutics outstanding shares are owned by institutional investors. These third-party entities are usually referred to as non-private investors looking to shop for positions in LENZ Therapeutics to benefit from reduced commissions. Thus, institutional holders are subject to a different set of regulations than regular investors in LENZ Therapeutics. Please pay attention to any change in the institutional holdings of LENZ Therapeutics as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check LENZ Ownership Details
LENZ Therapeutics Historical Income Statement
LENZ Stock Against Markets
LENZ Therapeutics Corporate Management
| Marvin Garrett | Senior Quality | Profile | |
| Breianna Bowen | Vice Resources | Profile | |
| David Murphy | Senior Development | Profile | |
| Daniel CPA | Chief Officer | Profile |
Additional Tools for LENZ Stock Analysis
When running LENZ Therapeutics' price analysis, check to measure LENZ Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy LENZ Therapeutics is operating at the current time. Most of LENZ Therapeutics' value examination focuses on studying past and present price action to predict the probability of LENZ Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move LENZ Therapeutics' price. Additionally, you may evaluate how the addition of LENZ Therapeutics to your portfolios can decrease your overall portfolio volatility.